Stockreport

Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point [Seeking Alpha]

Tectonic Therapeutic, Inc.  (TECX) 
PDF TECX is targeting CpcPH patients with PVR 3 in the ongoing phase 2 APEX study of PH-HFpEF, with topline data expected in 2026 and expansion into PH-ILD planned then als [Read more]